The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Leveraging social media for cardio-oncology
Narjust Florez, MD, of the University of Wisconsin Carbone Cancer Center, Madison, WI, outlines how social media can be used to connect patients and healthcare professionals to important resources as discussed in a recently published review. Dr Duma discusses the example of osimertinib, an EGFR inhibitor used in the treatment of lung cancer and a treatment associated with cardiac toxicities, and how social media can be used to collaborate between healthcare professionals of different specialties. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
